Co‐mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer

Osimertinib is designed to target the secondary resistant EGFR T790M mutant and has shown outstanding clinical efficacy. However, the prognostic prediction of osimertinib patients is a big problem in clinical practice. The resistance mechanism of osimertinib is also not fully understood. NGS and a 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, Puyuan, Han, Xiaohong, Wang, Sha, Liu, Yutao, Yang, Sheng, Hao, Xuezhi, Wang, Yan, Liu, Peng, Li, Junling, Wang, Lin, Chang, Lianpeng, Guan, Yanfang, Zhang, Zhishang, Wu, Di, Yao, Jiarui, Yi, Xin, Shi, Yuankai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787503/
https://www.ncbi.nlm.nih.gov/pubmed/31393074
http://dx.doi.org/10.1111/jcmm.14565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787503/
https://www.ncbi.nlm.nih.gov/pubmed/31393074
http://dx.doi.org/10.1111/jcmm.14565

Ejemplares similares